Cargando…

Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis

INTRODUCTION: Multiple sclerosis (MS) is a severe debilitating disease that affects patients' quality of life. Up to 90% of patients with MS will develop lower urinary tract dysfunction within the first 18 years of the disease. If oral pharmacotherapy with anticholinergics, behavioural modifica...

Descripción completa

Detalles Bibliográficos
Autores principales: Elizondo, Rodolfo A, Karmonik, Christof, Boone, Timothy B, Khavari, Rose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293986/
https://www.ncbi.nlm.nih.gov/pubmed/28159850
http://dx.doi.org/10.1136/bmjopen-2016-013225
_version_ 1782505162902863872
author Elizondo, Rodolfo A
Karmonik, Christof
Boone, Timothy B
Khavari, Rose
author_facet Elizondo, Rodolfo A
Karmonik, Christof
Boone, Timothy B
Khavari, Rose
author_sort Elizondo, Rodolfo A
collection PubMed
description INTRODUCTION: Multiple sclerosis (MS) is a severe debilitating disease that affects patients' quality of life. Up to 90% of patients with MS will develop lower urinary tract dysfunction within the first 18 years of the disease. If oral pharmacotherapy with anticholinergics, behavioural modifications and pelvic floor physical therapy are unsuccessful, intradetrusor injection of botulinum toxin-A (OnaBotA; Botox Allergan, Dublin, Ireland) is a highly effective option for these patients. The local effects of OnaBotA are well understood, but not much is known of its afferent/sensory effects while treating the end organ. Our study will use functional MRI (fMRI) and task-related blood oxygen level-dependent signals to evaluate patients with MS and neurogenic detrusor overactivity (NDO) prior to, and after, intradetrusor injection of OnaBotA with simultaneous urodynamic evaluation. Urinary concentration of brain-derived neurotrophic factor and nerve growth factor will also be collected since it has been shown that patients with an overactive bladder have higher concentrations of these neuropeptides. METHODS AND ANALYSIS: Female patients with MS and lower urinary tract symptoms who previously have undergone urodynamic screening and are refractory to conservative and oral pharmacotherapy management for NDO and are interested in OnaBotA intradetrusor injection will be invited to participate in the study. An fMRI will be performed preintradetrusor injection and postintradetrusor injection of OnaBotA with simultaneous MRI compatible with material urodynamics. Images will be collected and analysed accordingly. ETHICS AND DISSEMINATION: All of the patients are properly consented before enrolling in this study that has been previously approved by the Institutional Review Board. Results of neural connectivity activation will be presented at national and international meetings and published in scholarly journals.
format Online
Article
Text
id pubmed-5293986
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-52939862017-02-27 Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis Elizondo, Rodolfo A Karmonik, Christof Boone, Timothy B Khavari, Rose BMJ Open Urology INTRODUCTION: Multiple sclerosis (MS) is a severe debilitating disease that affects patients' quality of life. Up to 90% of patients with MS will develop lower urinary tract dysfunction within the first 18 years of the disease. If oral pharmacotherapy with anticholinergics, behavioural modifications and pelvic floor physical therapy are unsuccessful, intradetrusor injection of botulinum toxin-A (OnaBotA; Botox Allergan, Dublin, Ireland) is a highly effective option for these patients. The local effects of OnaBotA are well understood, but not much is known of its afferent/sensory effects while treating the end organ. Our study will use functional MRI (fMRI) and task-related blood oxygen level-dependent signals to evaluate patients with MS and neurogenic detrusor overactivity (NDO) prior to, and after, intradetrusor injection of OnaBotA with simultaneous urodynamic evaluation. Urinary concentration of brain-derived neurotrophic factor and nerve growth factor will also be collected since it has been shown that patients with an overactive bladder have higher concentrations of these neuropeptides. METHODS AND ANALYSIS: Female patients with MS and lower urinary tract symptoms who previously have undergone urodynamic screening and are refractory to conservative and oral pharmacotherapy management for NDO and are interested in OnaBotA intradetrusor injection will be invited to participate in the study. An fMRI will be performed preintradetrusor injection and postintradetrusor injection of OnaBotA with simultaneous MRI compatible with material urodynamics. Images will be collected and analysed accordingly. ETHICS AND DISSEMINATION: All of the patients are properly consented before enrolling in this study that has been previously approved by the Institutional Review Board. Results of neural connectivity activation will be presented at national and international meetings and published in scholarly journals. BMJ Publishing Group 2017-02-03 /pmc/articles/PMC5293986/ /pubmed/28159850 http://dx.doi.org/10.1136/bmjopen-2016-013225 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Urology
Elizondo, Rodolfo A
Karmonik, Christof
Boone, Timothy B
Khavari, Rose
Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis
title Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis
title_full Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis
title_fullStr Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis
title_full_unstemmed Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis
title_short Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis
title_sort protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-a in patients with multiple sclerosis
topic Urology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293986/
https://www.ncbi.nlm.nih.gov/pubmed/28159850
http://dx.doi.org/10.1136/bmjopen-2016-013225
work_keys_str_mv AT elizondorodolfoa protocolforaprospectiveobservationalstudyofcorticallowerurinarytractcontrolchangesfollowingintradetrusorinjectionofbotulinumtoxinainpatientswithmultiplesclerosis
AT karmonikchristof protocolforaprospectiveobservationalstudyofcorticallowerurinarytractcontrolchangesfollowingintradetrusorinjectionofbotulinumtoxinainpatientswithmultiplesclerosis
AT boonetimothyb protocolforaprospectiveobservationalstudyofcorticallowerurinarytractcontrolchangesfollowingintradetrusorinjectionofbotulinumtoxinainpatientswithmultiplesclerosis
AT khavarirose protocolforaprospectiveobservationalstudyofcorticallowerurinarytractcontrolchangesfollowingintradetrusorinjectionofbotulinumtoxinainpatientswithmultiplesclerosis